^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A case-control study of Fruquintinib combined with anti-PD-1 versus PD-1 in the treatment of metastatic colon cancer (a randomized, open-label phase II clinical trial)
Excerpt:
...1.Pathologically confirmed as colorectal cancer; 2.After radical resection of colorectal cancer; 3.Postoperative pathological staging stage II-III; 4.Confirmed as dMMR-MSI-H; 5.Distant metastasis occurred in postoperative review; 6.Aged 20 to 80 years; 7.ECOG score 0-1 points; 8.White blood cell count>4x10^9/L, platelet count>80x10^9/L, liver and kidney function normal, electrocardiogram normal, no immunotherapy contraindications....
Trial ID:
Source:
Title:
PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
Published date:
05/16/2022
Excerpt:
The patient was a young man in his 30s who had MSI-H type colon cancer. The patient underwent four cycles of neoadjuvant therapy with a PD-1 inhibitor combined with fruquintinib before surgery, resulting in regression of the mass and a successful surgery.
DOI:
10.12998/wjcc.v10.i14.4669
